Cargando…

CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease

Epstein-Barr virus (EBV) is a latent and oncogenic human herpesvirus. Lytic viral protein expression plays an important role in EBV-associated malignancies. The EBV envelope glycoprotein 350 (gp350) is expressed abundantly during EBV lytic reactivation and sporadically on the surface of latently inf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Slabik, Constanze, Kalbarczyk, Maja, Danisch, Simon, Zeidler, Reinhard, Klawonn, Frank, Volk, Valery, Krönke, Nicole, Feuerhake, Friedrich, Ferreira de Figueiredo, Constanca, Blasczyk, Rainer, Olbrich, Henning, Theobald, Sebastian J., Schneider, Andreas, Ganser, Arnold, von Kaisenberg, Constantin, Lienenklaus, Stefan, Bleich, Andre, Hammerschmidt, Wolfgang, Stripecke, Renata
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479496/ https://www.ncbi.nlm.nih.gov/pubmed/32953984 http://dx.doi.org/10.1016/j.omto.2020.08.005

Ejemplares similares

Spatiotemporally Skewed Activation of Programmed Cell Death Receptor 1–Positive T Cells after Epstein-Barr Virus Infection and Tumor Development in Long-Term Fully Humanized Mice
por: Danisch, Simon, et al.
Publicado: (2019)

PD-1 Blockade Aggravates Epstein–Barr Virus(+) Post-Transplant Lymphoproliferative Disorder in Humanized Mice Resulting in Central Nervous System Involvement and CD4(+) T Cell Dysregulations
por: Volk, Valery, et al.
Publicado: (2021)

Reconstructing the immune system with lentiviral vectors
por: Olbrich, Henning, et al.
Publicado: (2017)

Adult and Cord Blood-Derived High-Affinity gB-CAR-T Cells Effectively React Against Human Cytomegalovirus Infections
por: Olbrich, Henning, et al.
Publicado: (2020)

Signatures of T and B Cell Development, Functional Responses and PD-1 Upregulation After HCMV Latent Infections and Reactivations in Nod.Rag.Gamma Mice Humanized With Cord Blood CD34(+) Cells
por: Theobald, Sebastian J., et al.
Publicado: (2018)

EBV-gp350 Confers B-Cell Tropism to Tailored Exosomes and Is a Neo-Antigen in Normal and Malignant B Cells—A New Option for the Treatment of B-CLL
por: Ruiss, Romana, et al.
Publicado: (2011)

Non-viral TRAC-knocked-in CD19(KI)CAR-T and gp350(KI)CAR-T cells tested against Burkitt lymphomas with type 1 or 2 EBV infection: In vivo cellular dynamics and potency
por: Braun, Tobias, et al.
Publicado: (2023)

Repertoire characterization and validation of gB-specific human IgGs directly cloned from humanized mice vaccinated with dendritic cells and protected against HCMV
por: Theobald, Sebastian J., et al.
Publicado: (2020)

Correction: Repertoire characterization and validation of gB-specific human IgGs directly cloned from humanized mice vaccinated with dendritic cells and protected against HCMV
por: Theobald, Sebastian J., et al.
Publicado: (2021)

In Vivo Lentiviral Gene Delivery of HLA-DR and Vaccination of Humanized Mice for Improving the Human T and B Cell Immune Reconstitution
por: Kumar, Suresh, et al.
Publicado: (2021)

Treatment Advances in EBV Related Lymphoproliferative Diseases
por: Lv, Kebing, et al.
Publicado: (2022)

GMP development and preclinical validation of CAR-T cells targeting a lytic EBV antigen for therapy of EBV-associated malignancies
por: Zhang, Xi, et al.
Publicado: (2023)

Monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia
por: Rickmann, Mareike, et al.
Publicado: (2013)

EBV-Positive T/NK-Cell Lymphoproliferative Disease of Childhood
por: Hong, Mineui, et al.
Publicado: (2013)

Overview of EBV-Associated T/NK-Cell Lymphoproliferative Diseases
por: Kimura, Hiroshi, et al.
Publicado: (2019)

Opportunities to Target the Life Cycle of Epstein-Barr Virus (EBV) in EBV-Associated Lymphoproliferative Disorders
por: Dugan, James P., et al.
Publicado: (2019)

Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib
por: Pálmason, Róbert, et al.
Publicado: (2015)

Viral-Targeted Strategies Against EBV-Associated Lymphoproliferative Diseases
por: Hui, Kwai Fung, et al.
Publicado: (2019)

Challenges in Managing EBV-Associated T- and NK-Cell Lymphoproliferative Diseases
por: Sato, Yoshitaka
Publicado: (2018)

Immunology of EBV-Related Lymphoproliferative Disease in HIV-Positive Individuals
por: Shindiapina, Polina, et al.
Publicado: (2020)

ADA2 deficiency complicated by EBV-driven lymphoproliferative disease
por: Staples, Emily, et al.
Publicado: (2020)

Characteristic Histological Findings of Asymptomatic EBV-associated Lymphoproliferative Disorders in Tonsils
por: Jamiyan, Tsengelmaa, et al.
Publicado: (2018)

HHV-8 and EBV Positive Lymphoproliferative Disease: A Challenging Case
por: Bülbül, Göksenil, et al.
Publicado: (2022)

New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders
por: Quintanilla-Martinez, Leticia, et al.
Publicado: (2022)

Development of an Improved Epstein-Barr Virus (EBV) Neutralizing Antibody Assay to Facilitate Development of a Prophylactic gp350-Subunit EBV Vaccine
por: Liu, Hui, et al.
Publicado: (2020)

Epstein-Barr Virus (EBV)-Related Lymphoproliferative Disorders in Ataxia Telangiectasia: Does ATM Regulate EBV Life Cycle?
por: Tatfi, Moussab, et al.
Publicado: (2019)

The EBV Immunoevasins vIL-10 and BNLF2a Protect Newly Infected B Cells from Immune Recognition and Elimination
por: Jochum, Simon, et al.
Publicado: (2012)

The First Case of Concomitant Mycobacterium Genavense Lymphadenitis and EBV-Positive Lymphoproliferative Disorder
por: Ito, Yusuke, et al.
Publicado: (2020)

EBV reactivation mimicking a lymphoproliferative disorder associated with ruxolitinib therapy for myelofibrosis
por: Prem, Shruti, et al.
Publicado: (2019)

Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man
Publicado: (1991)

Designing and overproducing a tandem epitope of gp350/220 that shows a potential to become an EBV vaccine
por: Widodo, et al.
Publicado: (2018)

Induced dendritic cells co-expressing GM-CSF/IFN-α/tWT1 priming T and B cells and automated manufacturing to boost GvL
por: Bialek-Waldmann, Julia K., et al.
Publicado: (2021)

P-glycoprotein is expressed and causes resistance to chemotherapy in EBV-positive T-cell lymphoproliferative diseases
por: Yoshimori, Mayumi, et al.
Publicado: (2015)

EBV-Associated Lymphoproliferative Disorder and Hemophagocytic Lymphohistiocytosis in a Patient with Severe Celiac Disease
por: Kinross-Wright, John Jacob, et al.
Publicado: (2018)

HHV8/EBV Coinfection Lymphoproliferative Disorder: Rare Entity with a Favorable Outcome
por: Bacha, Dhouha, et al.
Publicado: (2017)

Intestinal ulcers as an initial finding in EBV-associated lymphoproliferative disorder: A case report
por: Wang, Sizhu, et al.
Publicado: (2020)

Fatal SARS-CoV-2 coinfection in course of EBV-associated lymphoproliferative disease
por: Roncati, Luca, et al.
Publicado: (2020)

Targeted Delivery of BZLF1 to DEC205 Drives EBV-Protective Immunity in a Spontaneous Model of EBV-Driven Lymphoproliferative Disease
por: Ahmed, Elshafa Hassan, et al.
Publicado: (2021)

Dissecting Epstein-Barr Virus-Specific T-Cell Responses After Allogeneic EBV-Specific T-Cell Transfer for Central Nervous System Posttransplant Lymphoproliferative Disease
por: Schultze-Florey, Rebecca E., et al.
Publicado: (2018)

EBV-Encoded MicroRNA-BART17-3p Targets DDX3X and Promotes EBV Infection in EBV-Associated T/Natural Killer–Cell Lymphoproliferative Diseases
por: Jin, Jin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h0lt3lge5g3ni54mrajp50pmso